Advertisement
Trikafta’s U.S. list price is over $322,000 a year. That is nearly 60 times the annual salary of a minimum wage earner in Turkey, where the government wanted to import a generic version made in Argentina. Vertex sued and blocked it.
Vertex has brought in $17 billion from Trikafta since 2019. An analysis by researchers in Britain found that a year’s supply of the drug could be manufactured for just $5,700.
Advertisement
The company says it is working to increase access to the drug globally.
(Except for the headline, this story has not been edited by PostX News and is published from a syndicated feed.)
